Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Breast Cancer. 2014 Feb;14(1):e14-6. doi: 10.1016/j.clbc.2013.09.010. Epub 2013 Sep 27.

Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib.

Author information

1
Foundation Medicine, Inc, Cambridge, MA.
2
Department of Pathology.
3
Department of Diagnostic Imaging, Fox Chase Cancer Center, Philadelphia, PA.
4
Foundation Medicine, Inc, Cambridge, MA; Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, NY.
5
Department of Pathology. Electronic address: Massimo.Cristofanilli@Jefferson.edu.

KEYWORDS:

HER2; Inflammatory breast cancer; Lapatinib; Next-generation sequencing; Trastuzumab

PMID:
24201163
DOI:
10.1016/j.clbc.2013.09.010
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center